Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-acetyl-4-guanidino-6-methyl(propyl)carboxamide-4,5-dihydro-2H-pyran-2-carboxylic acid
- Development stage
- Preclinical
- Lead developer
- Glaxo Wellcome
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule inhibitor designed as an analogue of sialic acid derivatives to target influenza virus neuraminidase. It features a pyran ring with multiple functional groups including acetyl, guanidino, methyl(propyl)carboxamide and carboxylic acid moieties. The molecule was developed for research purposes to study resistance mechanisms in influenza neuraminidase variants and has been used in structural biology studies to elucidate the binding interactions between neuraminidase inhibitors and both wild-type and mutant forms of the enzyme. Its primary mechanism is competitive inhibition of viral neuraminidase activity[3][5][8].
- Other names
- 5-N-acetyl-4-guanidino-6-methyl(propyl) carboxamide-4,5-dihydro-2H-pyran-2-carboxylic acid(2R,3R,4S)-3-acetamido–4-carbamimidamido–2-[methyl(propyl)carbamoyl]–3,4-dihydro–2H-pyran–6-carboxylic acid
02
Targets
Neuraminidase
Beyond the preview
Go deeper on 4-acetyl-4-guanidino-6-methyl(propyl)carboxamide-4,5-dihydro-2H-pyran-2-carboxylic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-acetyl-4-guanidino-6-methyl(propyl)carboxamide-4,5-dihydro-2H-pyran-2-carboxylic acid.